NYMX - NYMX STOCK NEWS

Nymox Pharmaceutical Corporation announces the issuance of important U.S. patents for NYMOZARFEX, expanding its patent portfolio. The patents cover treatments for prostate enlargement (BPH) and prostate cancer. CEO Paul Averback is the inventor behind the technology and patents.

Nymox Pharmaceutical Corporation provides additional information regarding recent changes in the board of directors and management. The company terminated the employment of its former in-house legal counsel and chief financial officer. They also rejected a potential transaction due to several reasons, including the excessive awards of up to 18 million shares of common stock to the former CFO and legal counsel, as well as the potential business partner not paying cash for certain rights but creating a debt on the company's balance sheet. The former CFO and legal counsel failed to disclose their roles in an unrelated company and sought financing from Nymox shareholders without disclosure. Nymox is focused on submitting applications for the approval of its drug NYMOZARFEX to treat benign prostatic hyperplasia (BPH), a common condition in middle-aged and elderly men with limited treatment options.

Nymox Pharmaceutical Corporation provides a mid-2nd quarter update on ongoing activities. The company expects to submit a new submission for marketing approval of Nymozarfex, its molecular treatment for benign prostate enlargement (BPH). Nymozarfex is a painless long-lasting treatment with no adverse effects, given once in a convenient office administration. The company has gained new patent approvals worldwide. BPH affects a large percentage of the male population and surgery is often needed. The company has submitted its application for Marketing Authorization Application to the Danish authorities.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced significant developments in its projects on April 3, 2023. The Company submitted a Marketing Authorization Application (MAA) to Danish authorities, accepted for review in February. A second submission is anticipated within 30-60 days. CEO Dr. Paul Averback highlighted the progress made in Q1 2023, emphasizing confidence in their first-in-class technology. The addition of Chris Riley to the management team has been well-received by shareholders. Nymox's Fexapotide, a treatment for BPH, has been administered in over 1,600 injections during clinical trials, demonstrating a strong safety profile and long-term improvements.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced the appointment of Christopher R. Riley as Chief Financial Officer. Riley has a robust background, having served as CFO for Frito-Lay Australia and CEO of PepsiCo Australia, where he achieved significant revenue growth. Dr. Paul Averback, President & CEO, expressed confidence in Riley's capabilities to drive Nymox's financial strategies. Additionally, Nymox's recent submission of its Market Approval Application (MAA) for its treatment for benign prostatic hyperplasia is under review in Denmark, highlighting ongoing efforts to address unmet medical needs in this sector.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has been granted an extension until July 3, 2023, by NASDAQ to regain compliance with its listing requirements. The company has submitted a Market Approval Application (MAA) for its treatment NYMOZARFEX (TM) targeting benign prostatic hyperplasia (BPH), a condition affecting many men worldwide. This first-in-class treatment offers long-term benefits without the common side effects of traditional therapies. The MAA is currently under review in Denmark, with further submissions expected soon. Nymox emphasizes the unmet medical need for better BPH treatments and the promising safety profile of Fexapotide.